Arrowstreet Capital
AKBA icon

Arrowstreet Capital’s Akebia Therapeutics AKBA Stock Holding History

Arrowstreet Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-27,500
Closed -$373K – 2305
2020
Q2 		$373K Buy
+27,500
New +$285K ﹤0.01% 2046
2019
Q2 		– Sell
-109,199
Closed -$894K – 1361
2019
Q1 		$894K Buy
+109,199
New +$749K ﹤0.01% 1347
2018
Q2 		– Sell
-52,500
Closed -$500K – 1063
2018
Q1 		$500K Buy
+52,500
New +$734K ﹤0.01% 958
2017
Q4 		– Sell
-121,089
Closed -$2.38M – 1226
2017
Q3 		$2.38M Buy
121,089
+82,189
+211% +$1.26M 0.01% 657
2017
Q2 		$559K Buy
38,900
+24,222
+165% +$307K ﹤0.01% 863
2017
Q1 		$135K Buy
+14,678
New +$143K ﹤0.01% 1218

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's AKBA Position: Q3 2020 in Review

Arrowstreet Capital sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 27,500 shares — an estimated $373K sold.

Arrowstreet Capital first reported a position in AKBA in Q1 2017 and held it in 6 quarters. The position peaked at $2.38M in Q3 2017. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Arrowstreet Capital reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 27,500 Akebia Therapeutics shares in Q3 2020, an estimated $373K.
  • Arrowstreet Capital first reported a position in Akebia Therapeutics in Q1 2017 and held it in 6 quarters.
  • Arrowstreet Capital's Akebia Therapeutics position peaked at $2.38M in Q3 2017.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.